Shield Therapeutics PLC

STX

Equity

ISIN GB00BYV81293 / Valor 29778101

LSE London Stock Exchange, SETS (2026-09-08)

GBP 0.051-15.3%

Shield Therapeutics PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Shield Therapeutics PLC operates as a specialty pharmaceutical company primarily engaged in the development and commercialization of pharmaceutical solutions for the treatment of iron deficiency. The company's flagship product, ACCRUFeR®, represents a novel approach in the oral treatment of adults suffering from iron deficiency, with or without anemia. This non-salt based therapy has gained approval in several major markets, including the United States, European Union, UK, and Switzerland, and is protected by exclusive intellectual property rights extending into the mid-2030s. As a commercial stage entity, Shield Therapeutics focuses on addressing the unmet medical needs of patients with iron deficiency, aiming to enhance their quality of life through its innovative treatment options. The company is listed on the AIM market of the London Stock Exchange, adhering to the stringent regulatory requirements and governance standards that this entails.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-34.8%1Y

-54.0%3Y

-88.3%5Y

Performance

70.7%1Y

94.7%3Y

92.8%5Y

Volatility